Detail
The product Halyx has been evaluated in a multicenter clinical study conducted in Italy, with the primary objective of assessing the efficacy and safety of non-crosslinked Hyaluronic Acid (HA) for skin rejuvenation and wrinkle reduction in the face and neck areas.
The study was carried out in Italian women aged 35–65 years presenting with moderate to deep wrinkles. Participants received four consecutive treatment sessions, followed by a three-month observation period.
Key findings of the study include:
- Significant wrinkle reduction was observed as early as the first month after treatment, with visible results lasting up to 4–5 months.
- More than 95% of participants reported satisfaction and recommended the treatment to others.
- Physician assessments confirmed that the majority of patients showed a clear and positive improvement (“Much Improved”).
- The treatment demonstrated a high safety profile, with only mild and transient side effects such as swelling and erythema at the injection site, which resolved spontaneously.
Conclusion
This clinical study reinforces that Halyx is a safe and highly effective option for the management of skin aging and wrinkle reduction. With results lasting 4–5 months per treatment cycle, and the possibility of repeating the treatment 2–3 times per year, Halyx represents a reliable solution for patients seeking natural and sustainable skin rejuvenation.
Reference:
U. Giaroli, M.I. D’Orso, P.D. Pigatto. A Clinical, Multicenter Study for the Evaluation of the Efficacy and Safety of HALYX Intradermal Injectable Non-Crosslinked HA Based Formulation in the Treatment of Skin Aging of the Upper District (Face and Neck). Aerazen Lab srl, Milano, Italy, 2015.
